Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab-Ac225 in Older Patients With Untreated AML
NCT02575963Phase 2Completed
- Sponsor
- Actinium Pharmaceuticals, Inc.
- Start
- Oct 2012
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of lintuzumab satetraxetan ac-225 in acute myeloid leukemia (AML) (2 arms), sponsored by Actinium Pharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose and Complete Remission Rate (CR + CRp + CRi) at Day 42. Started Oct 2012; status: completed.
02
Drugs
lintuzumab satetraxetan ac-225
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02575963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575963.